Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complement and myasthenia gravis

2 Sept 2022

Abstract excerpt

Myasthenia gravis is a neuromuscular disease associated with antibodies against components of the neuromuscular junction, most often against the acetylcholine receptor (AChR). Although several mechanisms have been postulated to explain how these autoantibodies can lead to the pathology of the disease, convincing evidence suggests that destruction of the receptor-bearing postsynaptic membrane by complement...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antifungal resistance and susceptibility
Share to Myasthenia Gravis and Thymoma
Share to Peripheral Neuropathies and Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36063582
DOI: 10.1016/j.molimm.2022.08.018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complement and myasthenia gravisPMID 36063582Read ↗

The role of complement in the immunopathogenesis of acetylcholine receptor antibody-positive generalized myasthenia gravis: bystander or key player?Semantic proximity Read ↗

Pathogenesis of myasthenia gravis: update on disease types, models, and mechanismsSemantic proximity Read ↗

Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificitiesSemantic proximity Read ↗

Complement inhibition by C3-siRNA treatment prevents AChR loss and reduces complement activation in the rat Passive Transfer Myasthenia Gravis (PTMG)Semantic proximity Read ↗

Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief reviewSemantic proximity Read ↗

Heterogeneity of acetylcholine receptor autoantibody-mediated complement activity in patients with myasthenia gravisSemantic proximity Read ↗

Distribution and Temporal Changes of Autoantibody-Mediated Pathogenic Mechanisms Among Acetylcholine Receptor-Positive Myasthenia Gravis PatientsSemantic proximity Read ↗

Myasthenia gravis: from autoantibodies to therapy.Semantic proximity Read ↗

Molecular targets for autoimmune and genetic disorders of neuromuscular transmission.Semantic proximity Read ↗

Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis.Semantic proximity Read ↗

Exploring Myasthenia Gravis Subtypes: Impact on Pregnancy and Recent Treatment AdvancementsSemantic proximity Read ↗

Clinical aspects of myasthenia explained.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.